| Next 10 |
Ad
AIMD News and Press Ainos Inc
News | Ainos Inc (OTCMKTS:AIMD)
-
2023-09-25 08:56:23 ET More on Ainos Financial information for Ainos For further details see: Ainos to issue initial $3M tranche of $10M private placement of notes
-
Proceeds to fund company's clinical trials, commercial product launch, and working capital Initial conversion price set at $1.50 per share SAN DIEGO, CA / ACCESSWIRE / September 25, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company fo...
-
Boston, Massachusetts--(Newsfile Corp. - September 19, 2023) - The U.S. Food and Drug Administration (FDA) has granted Ainos' (NASDAQ: AIMD) VELDONA Orphan Drug Designation (ODD) for the treatment of oral warts in HIV-seropositive patients. VELDONA is Very Low-Dose Oral Interferon Alpha, Ainos' p...
-
VELDONA® positioned as a potential treatment option for over 24,000 HIV-seropositive Americans SAN DIEGO, CA / ACCESSWIRE / September 18, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of AI-powered point...
-
First Batch of 300,000 Units to be Fully Delivered in October Ainos Has Expanded Distribution in Multiple Channels and Plans to Scale Up Capacity for Expected Strong Demand SAN DIEGO, CA / ACCESSWIRE / September 5, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a ...
-
Boston, Massachusetts--(Newsfile Corp. - August 15, 2023) - Here at Horizon Insights, we see two big trends right now in healthcare - the emergence of Artificial Intelligence, or AI platforms, and the growing prevalence and acceptance of Telehealth. Ainos, Inc. (NASDAQ: AIMD), a diversified healt...
-
2023-08-11 16:56:19 ET Ainos press release ( NASDAQ: AIMD ): Q2 GAAP EPS of -$0.12. Revenue of $0.03M (-95.0% Y/Y). As of June 30, 2023, the Company had cash and cash equivalents of US$1,360,970 compared with US$1,853,362 as of December 31, 2022. For further deta...
-
Strategic Focus Continues to Pivot from COVID to Pet Health and AI-powered Testing Launch of VELDONA® Pet Provides New Revenue Stream for Near-Term; Ainos Flora Remains on Horizon for 2024 SAN DIEGO, CA / ACCESSWIRE / August 11, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or ...
-
Ainos reflects upon multiple business milestones following Nasdaq listing, as it diversifies its revenues and advances its product pipeline SAN DIEGO, CA / ACCESSWIRE / August 10, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on...
-
The Collaboration Signals Era of New Innovation for AI Nose Technology for Broader Industry Adoption With Partnership, Ainos Makes Progress Towards Mission of Digitizing Smell SAN DIEGO, CA / ACCESSWIRE / August 9, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a d...
Stock Information
Ainos Inc Company Name:
AIMD Stock Symbol:
OTCMKTS Market:
Ad
-
Proceeds to fund company's clinical trials, commercial product launch, and working capital Initial conversion price set at $1.50 per share SAN DIEGO, CA / ACCESSWIRE / September 25, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company fo...
-
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares climbed 81.5% to $0.2793 after jumping 64% on Wednesday. Near Intelligence, Inc. (NASDAQ: NIR) g...
-
Boston, Massachusetts--(Newsfile Corp. - September 19, 2023) - The U.S. Food and Drug Administration (FDA) has granted Ainos' (NASDAQ: AIMD) VELDONA Orphan Drug Designation (ODD) for the treatment of oral warts in HIV-seropositive patients. VELDONA is Very Low-Dose Oral Interferon Alpha, Ainos' p...